The Evidence
The strongest evidence is for spasticity:
- Multiple Sativex/nabiximols RCTs — consistent improvements in patient-reported spasticity, sleep, and quality of life. Approved in 29+ countries (UK, Germany, Canada, Spain, etc.) specifically for MS spasticity that hasn’t responded adequately to other antispasticity medication.
- 2017 NASEM report — rated cannabis evidence for spasticity in MS as "substantial."
- 2014 American Academy of Neurology guideline — concluded that oral cannabis extract is effective and that THC and nabiximols are probably effective for reducing patient-reported spasticity symptoms in MS.
Evidence for cannabis benefit in MS pain, bladder symptoms, and tremor is weaker but suggestive. Evidence for cannabis modifying disease course (preventing relapses or progression) is essentially absent — cannabis is symptom management, not a disease-modifying therapy.
The Sativex / Nabiximols Story
Sativex is a botanical cannabis extract standardized to 2.7 mg THC and 2.5 mg CBD per 100 microliter spray — effectively a 1:1 ratio. Patients self-titrate up to typically 8–12 sprays per day, sublingually.
It is approved in 29+ countries for spasticity associated with MS. It is not FDA-approved in the US (one phase 3 cancer-pain trial failed; cancer is the indication GW Pharma pursued in the US). This means American MS patients have to access either a non-approved similar formulation through a state medical-cannabis program, or go through a clinical trial.
What to Use If You Can’t Get Sativex
The closest available approximation in US dispensaries is a 1:1 THC:CBD sublingual tincture. Many dispensaries in legal states stock these. Look for products with verified Certificates of Analysis showing the 1:1 ratio.
Alternative options:
- 1:1 capsules — oral; longer onset (60–120 min) but more predictable for chronic dosing.
- 1:1 transdermal patches — sustained delivery over 12–24 hours; useful for steady-state spasticity control.
- CBD-dominant tincture (e.g., 20:1 CBD:THC) — if THC psychoactivity is undesirable; lower spasticity efficacy but better tolerability.
- Topical balm on muscle groups with focal spasticity — supplements systemic treatment.
Starting dose for older adults with MS
Begin at 2.5–5 mg of THC + 2.5–5 mg of CBD sublingually, once daily, in the evening (so you can rest if THC sedation is significant). Increase by 2.5 mg every 3–7 days as tolerated, up to a typical effective range of 10–25 mg of each cannabinoid per day total, divided into 2–4 doses.
If spasticity is intermittent (worse at certain times), dose 30–90 minutes before the predictable flare.
Drug Interactions
MS medication regimens vary enormously by disease type and stage. Common interactions to flag:
- Baclofen, tizanidine, dantrolene — antispasticity medications. Cannabis adds to their effect; coordinated dose adjustment may allow lower doses of either.
- Benzodiazepines (diazepam, clonazepam) — commonly used for spasticity and anxiety. Additive sedation with cannabis — reduce starting cannabis dose.
- Disease-modifying therapies (DMTs) — interferons, glatiramer, fingolimod, ocrelizumab, natalizumab, dimethyl fumarate, etc. Most don’t have direct cannabis interactions, but CBD’s CYP450 inhibition can theoretically affect blood levels of some DMTs. Discuss specifically with your neurologist.
- Opioids and gabapentinoids — for pain. Additive sedation with cannabis; cannabis may allow opioid dose reduction.
- Anticholinergics for bladder symptoms — cannabis can compound dry mouth and constipation.
Coordination with your MS team is essential before adding cannabis. See Cannabis Drug Interactions.
What MS Patients Often Use Cannabis For (Beyond Spasticity)
- Sleep — both spasticity and pain disrupt sleep; cannabis can help fall-asleep latency. See Cannabis for Sleep Elderly.
- Neuropathic pain — central pain syndromes are common in MS; cannabis evidence for neuropathic pain is strong. See Cannabis for Neuropathy.
- Bladder symptoms — some patients report symptom improvement; evidence is mixed.
- Tremor — mostly anecdotal; small trials show modest effects.
- Mood and anxiety — depression is common in MS; CBD-dominant products may help without compounding cognitive effects.
Considerations Specific to MS
- Cognitive symptoms — MS itself can cause cognitive changes. THC adds short-term cognitive effects. Patients with significant baseline cognitive impairment should weigh this carefully and start at very low doses.
- Falls and balance — MS already affects balance; THC sedation compounds the fall risk. Avoid daytime THC if you ambulate independently. See Cannabis, Falls, and Balance.
- Heat sensitivity — THC can cause thermoregulatory changes; many MS patients are heat-sensitive (Uhthoff’s phenomenon).
- Driving — MS often already affects reaction time; cannabis adds to that. See Driving & Cognitive Effects.
Bottom Line
Cannabis for MS spasticity has the strongest evidence in the MS-symptom-management literature outside the disease-modifying therapies. A 1:1 THC:CBD product (sublingual tincture being the easiest US-legal proxy for Sativex) is the evidence-based starting point. Begin at very low doses, coordinate with your MS team about interactions with antispasticity medications and DMTs, and watch the cognitive and balance side effects extra carefully because MS itself affects those systems.